HS-10296 |
| Catalog No.GC39560 |
HS-10296 (HS-10296) es un inhibidor irreversible de la tirosina cinasa de EGFR de tercera generaciÓn disponible por vÍa oral con alta selectividad para las mutaciones de resistencia a T790M y de sensibilizaciÓn de EGFR. HS-10296 muestra una gran actividad inhibitoria frente a T790M, T790M/L858R y T790M/Del19 (IC50: 0,37, 0,29 y 0,21 nM, respectivamente), y es menos eficaz frente al tipo salvaje (3,39 nM). HS-10296 se utiliza para la investigaciÓn del cÁncer de pulmÓn de células no pequeÑas.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1899921-05-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
HS-10296, an orally available and third-generation EGFR-activating mutations and T790M-resistant mutation inhibitor, shows limited activity against wild-type EGFR[1][2].
[1]. Sullivan I, et al. Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line. Front Med (Lausanne). 2017 Jan 18;3:76. [2]. Wu SG, et al. Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. Mol Cancer. 2018 Feb 19;17(1):38.
Average Rating: 5 (Based on Reviews and 29 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *